Positivity for antinuclear antibody in patients with advanced rheumatoid arthritis.
20
Citation
0
Reference
10
Related Paper
Citation Trend
Abstract:
Some patients with rheumatoid arthritis (RA) as well as those with other collagen diseases are positive for antinuclear antibody (ANA). We investigated the frequency of positivity for ANA in 104 patients with RA and evaluated the clinical features and laboratory data in the ANA-positive and -negative groups. The presence of ANA in sera was studied by indirect immunofluorescence using HEp-2 cells as the antigen substrate. Sera with a positive fluorescence at a dilution of 1:20 were considered to be positive for ANA. Of the 104 patients, 39 (37.5%) were positive for ANA. The staining pattern in the positive cases varied, but most were speckled (64.1%) and homogeneous (48.7%). A small number showed a nucleolar (20.5%) or a centromere (10.3%) pattern. None showed a shaggy pattern. The ANA titer was lower in RA patients compared with those with other collagen-related diseases such as systemic lupus erythematosus or progressive systematic sclerosis. None of the patients positive for ANA with either a nucleolar or centromere staining pattern had progressive systemic sclerosis or the CREST syndrome. One patient each had Raynaud's phenomenon and pulmonary fibrosis. There was no correlation between ANA positivity and indicators of joint inflammation. The prevalence of ANA positivity in patients with advanced or prolonged disease was higher than those with early stages or short durations. There was no correlation with drug therapy.Keywords:
CREST Syndrome
Scleroderma (fungus)
Sera from 84 patients with progressive systemic sclerosis (PSS) were tested for the presence of antinuclear antibodies by immunofluorescence on HEp2 cells and gel immunodiffusion. Fluorescent antinuclear antibodies were detected in 80 subjects with PSS (95%). Ninety-three percent of patients with CREST syndrome and 3% of those with diffuse scleroderma had a centromere staining. Precipitating antibodies were found in 57% of PSS sera and identified as anti-Scl 70 in 42 cases (50%). This specificity was found in 42 of 70 subjects with diffuse scleroderma (60%); another patient was positive for anti-nRNP antibodies, and 5 more sera from PSS patients showed precipitin lines of unknown specificity. No serum from 14 patients with CREST syndrome was positive for anti-Scl 70 antibodies. Significant relationships have been found between centromere staining and CREST syndrome (p less than 0.0005) and between the presence of anti-Scl 70 antibodies and the diffuse form of scleroderma (p less than 0.0005). The latter specificity is strongly associated with grainy speckled pattern on HEp2 fluorescence (p less than 0.0005). These data suggest that anti-Scl 70 antibodies and anti-centromere antibodies are useful markers for different subgroups of patients with PSS.
Scleroderma (fungus)
CREST Syndrome
Immunofluorescence
Systemic scleroderma
Ouchterlony double immunodiffusion
Cite
Citations (29)
CREST Syndrome
Extractable nuclear antigens
Cite
Citations (13)
Type II collagen
Cite
Citations (28)
Using a newly developed enzyme-linked immunosorbent assay, antibodies to histones (H1, H2A, H2B, H3 and H4) were found in 32 out of 40 rheumatoid arthritis patients with antinuclear antibodies at a titer greater than or equal to 100 as measured by indirect immunofluorescence. The anti-H2A reactivity was higher in patients with secondary Sjögren's syndrome than in those without, but the highest antihistone reactivity and the most heterogeneous patterns were observed in patients who were receiving D-penicillamine.
Penicillamine
Immunofluorescence
Reactivity
Cite
Citations (11)
Profiles of autoantibodies in patients with scleroderma were reviewed and their possible clinical significance was discussed in this paper.Many autoantibodies including antinuclear antibodies and rheumatoid factors are detected in patients with scleroderma, especially in those with hypergammaglobulinemia. Fluorescent antinuclear antibodies were found in 36-97% of the serum of patients with scleroderma. The specificities of these antinuclear antibodies have been actively investigated in various laboratories using various nuclear antigens and many specificities were recently identified. Among them, two new antibody systems; anti-Og (Scl-1/Scl-70) antibody and anti-centromere antibody, were found to be highly specific for this disorder. Anti-Og antibody was detected in 33% of scleroderma patients and the patients with this antibody tended to have relatively advanced dermal sclerosis and pulmonary fibrosis. Anti-centromere antibody was reported to be present in the serum of patients mainly with CREST syndrome. Other antinulcear antibody systems; e.g. anti-DNA, anti-RNP, and anti-SS·B, were also seen in patients with scleroderma. However, when the patients with overlap syndrome were excluded, anti-RNP antibody was major antibody system in scleroderma. In contrast to the patients with anti-Og antibody, those with antiRNP antibody tended to have much milder sclerodermatous skin change and better prognosis.The presence of the serum autoantibodies in scleroderma patients and the association of these antibodies to patient's clinical characteristics suggest that these antibodies may play some significant roles in developping clinical features and/or might be closely related to the pathogenesis of this disease. Therefore it seems to be important to investigate these antibodies in order to clarify the pathogenesis of scleroderma.
Scleroderma (fungus)
CREST Syndrome
Extractable nuclear antigens
Clinical Significance
Cite
Citations (2)
Scl 70 antibodies were tested for in 107 patients with systemic sclerosis: 68 with acrosclerosis and 39 with diffuse scleroderma. Anticentromere antibodies (ACA) and other antinuclear antibodies (ANA) were tested for by indirect immunofluorescence on HEp-2 cells. Positive results for Scl 70 antibodies were obtained in 77% of cases of diffuse scleroderma and 44% of acrosclerosis. ACA and Scl 70 antibodies were found to be mutually exclusive. If acrosclerosis cases positive for anticentromere antibodies are excluded, the percentage of acrosclerosis cases positive for Scl 70 was 63%. ACA were found to be a marker of a benign, abortive subset of acrosclerosis with almost no cutaneous involvement (CREST), whereas Scl 70 did not discriminate between acrosclerosis and diffuse scleroderma. On HEp-2 cells Scl 70 positive sera gave a characteristic, fine speckled, almost homogeneous nuclear staining pattern.
Scleroderma (fungus)
CREST Syndrome
Immunofluorescence
Systemic scleroderma
Cite
Citations (88)
The prevalence of fungal complement-fixing antibodies in sera from 58 patients with sarcoidosis was determined and compared to complement-fixing antibody titers in 50 sera from a normal control group and 50 antinuclear antibody-positive sera. Sera from 9 patients with sarcoidosis had complement-fixing antibody titers greater than 1:8 to Histoplasma yeast antigen; serum from one normal control subject had a titer greater than 1:8; and none of the antinuclear antibody-positive sera demonstrated titers greater than 1:8. There were no significant complement-fixing antibody concentrations observed against histoplasmin, blastomycin, and coccidioidin antigens in any serum from the 3 groups studied. The increase in antibody titers to the Histoplasma yeast antigen might have been related to the generalized increase in immunoglobulin concentrations noted in patients with sarcoidosis.
Antibody titer
Cite
Citations (8)
The HEp2 cell cultures appeared highly sensitive in detecting the antinuclear antibodies (ANAb) in systemic sclerosis, principally anticentromere antibodies of the CREST syndrome. The immunoblotting used with either complex cellular extracts from HeLa and rabbit thymus or purified nuclear components (high mobility group (HMG) proteins and histones) is able to identify precisely the ANAb targets and to contribute to diagnosis. With nuclear extracts of HeLa cells, the sera from 75.8% of CREST syndrome subjects stained 18 and 22 kD proteins. Corresponding antibodies were also detected in 72.7% of these patients, on HEp2 centromers by indirect immunofluorescence. With the same extracts, 33.3% of sera from diffuse sclerosis/acrosclerosis patients contain antibodies staining 86, 73, 32 and 30kD. These sera also stain 77, 66 and 63kD from thymus extracts. Corresponding antibodies will be the anti-SCL-70 antibodies defined by double immunodiffusion. The anti-HMG antibodies were infrequent in systemic sclerosis, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) and consequently without interest for diagnosis. The anti-whole histones antibodies which are less frequent in diffuse sclerosis/acrosclerosis (35.7%) than in SLE (41.3%) recognize especially H1 and H2A in the first diseases, H1 and H2B in SLE and H1 and H3 in RA.
CREST Syndrome
Immunofluorescence
Scleroderma (fungus)
HeLa
Cite
Citations (14)
To measure the presence of autoantibodies binding to intact human recombinant collagen IX and assess their usefulness as a diagnostic marker and an indicator of disease activity in rheumatoid arthritis (RA).Recombinant human full-length collagen IX (rCIX) was produced in a baculovirus expression system and purified for use in ELISA developed to detect antibodies to native and denatured collagen IX. Fifty-three patients with recent-onset rheumatoid factor-seropositive RA were analyzed for the presence of rCIX antibodies of the IgG type at the time of initial diagnosis and after 3, 6, 12, and 24 months of followup. The RA sera were accompanied by 30 controls. Associations were determined between patients' antibody titers, development of erosions in the hands and feet, and various clinical and laboratory markers.Serum antibody levels among patients with RA at time of diagnosis were 1.78 times higher against native rCIX (p < 0.001) and 1.71 times higher against denatured rCIX (p < 0.001) than in the controls, and they remained high during the followup. No correlation was seen between antibody levels and clinical and laboratory findings.Our data show that patients with recent-onset RA have significantly elevated levels of autoantibodies to human rCIX. These autoantibodies were observed already at the early stages of the disease, which may reflect their diagnostic potential in RA.
Rheumatoid factor
Antibody titer
Cite
Citations (5)
Introduction and Aim: Rheumatoid arthritis an autoimmune disease is the most frequent kind of inflammatory arthritis and a leading cause of disability in the United States. The study's goal was to determine whether or not individuals with Rheumatoid Arthritis were positive for Toxoplasma antibodies while receiving biological therapy. Materials and Methods: By ELISA method Toxoplasma antibodies were investigates in serum of 100 RA patients under treatment with TNF-? antagonist from 4-6 months, and in serum from 100 healthy controls. Results: A statistically significant difference was found between patients and controls in the proportion of Toxoplasma antibodies (IgM 6, IgG 16 positive individuals). There was no correlation identified between Toxoplasma antibody seropositivity and responsiveness to biological treatments or disease activity. Conclusion: Toxoplasma antibody seropositivity may be associated with rheumatoid arthritis among Iraqi patients under biological drugs.
Rheumatoid factor
Cite
Citations (1)